Company
Pacira BioSciences, Inc.
Headquarters: Parsippany, NJ, United States
Employees: 697
CEO: Mr. David M. Stack
Market Cap
$1.13 Billion
USD as of Jan. 1, 2025
Pacira BioSciences, Inc. Categories
United States Healthcare Drug Manufacturers—Specialty & GenericUnited States Healthcare United States Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $675.0 M |
| EBITDA | $171.2 M |
| Gross Profit TTM | $490.3 M |
| Profit Margin | 6.22% |
| Operating Margin | 18.74% |
| Quarterly Revenue Growth | 5.40% |
Stocks & Indices
Pacira BioSciences, Inc. has the following listings and related stock indices.
Stock: NASDAQ: PCRX wb_incandescent
Stock: FSX: 82P wb_incandescent